Glucocorticoid-induced osteoporosis in rheumatic diseases.
about
Epidemiology and management of osteoporosis in the People's Republic of China: current perspectivesSteroids: pharmacology, complications, and practice delivery issuesEvaluating osteoporotic fracture risk with the Fracture Risk Assessment Tool in Chinese patients with rheumatoid arthritis.Osteoprotegerin Polymorphisms in a Mexican Population with Rheumatoid Arthritis and Generalized Osteoporosis: A Preliminary ReportLevel of Adherence to Prophylactic Osteoporosis Medication amongst Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: A Cross-Sectional Study.A review of the use of dual-energy X-ray absorptiometry (DXA) in rheumatology.Can side effects of steroid treatments be minimized by the temporal aspects of delivery method?Management considerations for childhood-onset systemic lupus erythematosus patients and implications on therapy.Long-term side effects of glucocorticoids.Physiological Bone Remodeling: Systemic Regulation and Growth Factor Involvement.RANKL and OPG gene polymorphisms: associations with vertebral fractures and bone mineral density in premenopausal systemic lupus erythematosus.Prevalence and possible risk factors of low bone mineral density in untreated female patients with systemic lupus erythematosus.Decreased quantity and quality of the periarticular and nonperiarticular bone in patients with rheumatoid arthritis: a cross-sectional HR-pQCT study.Factors influencing spinal sagittal balance, bone mineral density, and Oswestry Disability Index outcome measures in patients with rheumatoid arthritis.A randomized double-blind placebo-controlled trial of vitamin D supplementation in juvenile-onset systemic lupus erythematosus: positive effect on trabecular microarchitecture using HR-pQCT.
P2860
Q27005978-DC5DF08C-DA27-4ACD-8D9E-60F83AE4B234Q27015022-AE3D127B-CE6B-4106-9B77-85BAD4299B95Q33644108-AF2753F6-C512-4B13-8323-989AA2602EFCQ35612713-DA9FA204-F948-4848-ACD9-21C3CD5B1B5BQ36154597-7C16CB7E-A9A4-4C3B-895B-4410C241355EQ37301169-4E2CB706-0E40-40A9-B5E3-D17F6BC14338Q38254723-75F2F173-3757-4102-9F6E-C53BC53368C4Q38640910-A9D0B6BA-2C9D-4E21-9B0D-0E33D53BFC9CQ38703908-99337A57-AEA6-4284-92F3-2E92F2D117BEQ38800361-79DCEDC0-8D25-414D-9730-789F2C1840B5Q41547345-6C6E7277-1DA6-45FC-92EB-4C971FF69F0BQ42073555-4A047476-1753-44E7-B3E0-DEBF7151E567Q44303831-071CEFD8-2B27-41FD-9F43-B47C07C53EFDQ47304222-222AF9DE-8080-4383-883A-2A00FDB76C02Q47575714-30BDBB5A-6F55-4D52-BBFA-4E2879DE47D6
P2860
Glucocorticoid-induced osteoporosis in rheumatic diseases.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Glucocorticoid-induced osteoporosis in rheumatic diseases.
@ast
Glucocorticoid-induced osteoporosis in rheumatic diseases.
@en
Glucocorticoid-induced osteoporosis in rheumatic diseases.
@nl
type
label
Glucocorticoid-induced osteoporosis in rheumatic diseases.
@ast
Glucocorticoid-induced osteoporosis in rheumatic diseases.
@en
Glucocorticoid-induced osteoporosis in rheumatic diseases.
@nl
prefLabel
Glucocorticoid-induced osteoporosis in rheumatic diseases.
@ast
Glucocorticoid-induced osteoporosis in rheumatic diseases.
@en
Glucocorticoid-induced osteoporosis in rheumatic diseases.
@nl
P2093
P2860
P1433
P1476
Glucocorticoid-induced osteoporosis in rheumatic diseases.
@en
P2093
Ernesto Canalis
Jozélio Freire de Carvalho
Rosa Maria Rodrigues Pereira
P2860
P304
P356
10.1590/S1807-59322010001100024
P5008
P577
2010-01-01T00:00:00Z